Phreesia (PHR)
(Delayed Data from NYSE)
$21.96 USD
+0.02 (0.09%)
Updated May 9, 2024 04:00 PM ET
After-Market: $21.94 -0.02 (-0.09%) 5:06 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.96 USD
+0.02 (0.09%)
Updated May 9, 2024 04:00 PM ET
After-Market: $21.94 -0.02 (-0.09%) 5:06 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Zacks News
Wall Street Analysts See a 38% Upside in Phreesia (PHR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Phreesia (PHR) points to a 37.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Phreesia (PHR) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Phreesia (PHR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Think Phreesia (PHR) Could Surge 26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 25.5% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Phreesia (PHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nextgen Healthcare (NXGN) Q4 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -5% and 0.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Surges 7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Phreesia (PHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (MTBC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareCloud, Inc. (MTBC) delivered earnings and revenue surprises of 29.63% and 5.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0% and 27.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Company News for Dec 10, 2021
by Zacks Equity Research
Companies in The News Are: GME,GEF,PHR,NAPA
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -51.06% and 15.19%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 6th
by Zacks Equity Research
BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.
Earnings Preview: Phreesia (PHR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for November 29th
by Zacks Equity Research
DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -118.18% and 8.71%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Phreesia (PHR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 6th
by Zacks Equity Research
DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021
Phreesia (PHR) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Phreesia (PHR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Analysts Estimate Phreesia (PHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -20.00% and 5.74%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?